Daily Humiome Post LB for wellbeing in older adults with moderate stress
A Randomised, Placebo-controlled, Double-blind Clinical Trial to Evaluate the Efficacy of Three Months Daily Ingestion of Humiome® Post LB on Wellbeing in 50 - 75 Year-old Adults in France
This trial will test whether taking Humiome® Post LB daily for three months lowers self-reported stress in people aged 50–75 with moderate stress.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 50 Years to 75 Years |
| Sex | All |
| Sponsor | dsm-firmenich Switzerland AG Industry-sponsored |
| Locations | 1 site (Saint-Herblain) |
| Trial ID | NCT07471659 on ClinicalTrials.gov |
What this trial studies
PostWelLB is a randomized, double-blind, placebo-controlled, parallel-group trial giving participants either 340 mg/day of Humiome® Post LB or placebo for three months. Eligible participants are adults aged 50–75 in France with moderate perceived stress (PSS-10 scores 14–26) and BMI 18.5–<30 kg/m2. Humiome® Post LB is a postbiotic made from heat-inactivated Limosilactobacillus fermentum and Lactobacillus delbrueckii plus a metabolite-rich fermentation medium and lactose, and the trial uses the validated PSS-10 questionnaire as the primary outcome. The product evolved from the long-used Lactéol formulation with an established digestive safety record, and the trial builds on preclinical data suggesting possible mood and stress effects.
Who should consider this trial
Good fit: Ideal candidates are men and women aged 50–75 with BMI 18.5–<30 kg/m2, PSS-10 scores of 14–26, women not at risk of pregnancy (or menopausal without recent hormone replacement), and who can comply with clinic visits in France.
Not a fit: People with severe stress outside the trial range (PSS-10 <14 or >26), major psychiatric disorders or active medical conditions, pregnant or breastfeeding women, or those unable to attend study visits are unlikely to receive benefit from this trial.
Why it matters
Potential benefit: If effective, Humiome® Post LB could provide a well-tolerated daily supplement to reduce perceived stress and support wellbeing in older adults.
How similar studies have performed: Lactéol-derived products have a long safety record for digestive benefits and HPLB showed mood and stress effects in animal studies, but clinical evidence for stress reduction in humans is currently limited.
Eligibility criteria
Show full inclusion / exclusion criteria
INCLUSION CRITERIA: * Men and women aged between 50 and 75 years old (limits included), * Body mass index (BMI) ≥ 18.5 and \< 30 kg/m² * Presenting a level of psychological stress characterized by a PSS-10 score ≥ 14 and ≤ 26, * For women: not at risk of pregnancy (as per definitions of Appendix 13) Participants currently of childbearing potential, using an effective method of contraception. * Menopausal without hormone replacement therapy (estrogenic replacement therapy stopped since more than 3 months can be included) * Good general and mental health according to the opinion of the investigator: No relevant abnormalities from medical history nor from the medical consultation * Agreeing to maintain lifestyle habits during the study (same dietary and physical activity habits) * Able and willing to participate to the trial by complying with the protocol procedures as evidenced by a dated and signed ICF * Affiliated with a social security scheme, * With access to a health-care provider, who can be contacted by the CRO, and who reside in areas with available emergency health services, * Agreeing to be registered in the national database of subjects participating in clinical research, * Having a smartphone or personal computer compatible with the eConsult and ePRO applications. EXCLUSION CRITERIA: * Suffering from a metabolic disorder such as treated or untreated diabetes, * Suffering from thyroid dysfunction, high blood pressure or other metabolic disorders treated for less than 6 months and/or non-stabilized, * Suffering from a severe chronic disease: cancer, HIV, renal failure, hepatic or biliary disorders ongoing (except for cholecystectomy since more than two years and asymptomatic), chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble (except for mild asthma under treatment), * Suffering from GI disorders found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease, Chron's disease, etc.), * With a known food allergy or intolerance or hypersensitivity to any of the trial products' ingredients, * Women who are pregnant or lactating or intend on becoming pregnant within the following six months, * Having a history or presence of a psychiatric or neurologic disease including epilepsy, cerebrovascular disturbance, traumatic brain injury, dementia, Alzheimer's Disease, clinical depression, or other clinically significant psychiatric/neurologic condition that could interfere with the interpretation of the study results in the opinion of the investigator, * Having recently experienced or currently experiencing a significant stress as per investigator's judgment (e.g. grieving, divorce, moving, etc.), * Having a condition and/or receiving a treatment that may cause immunosuppression (e.g.: under immunomodulating treatment for HIV infection, allograft, auto-immune disease or cancer, etc.) * Under treatment or dietary supplement which could significantly affect parameter(s) followed during the trial according to the investigator or stopped less than one month prior to V1, * Under treatment with one or more of the following treatments stopped less than one month prior to V1: * psychotropic medications (including antidepressants and tranquilizers), stimulant medications, and/or narcotics having an effect on stress, sleep aid medications, supplements, and/or products, including antihistamines, acid-blocking medication (e.g., proton pump inhibitor, H2 blocker), * Under treatment with an effect on the microbiome such as antibiotics stopped less than one month prior to V1, * Having a lifestyle deemed incompatible with the trial according to the Investigator as described below: * Practicing a high-level of physical activity (defined as more than 10 hours of intense physical activity a week, walking excluded), * Regularly consuming more than 2 standard drinks of alcohol daily or 14 weekly or not agreeing to keep alcohol consumption habits unchanged throughout the study, * With a significant change in dietary or physical activity habits in the 3 months prior to randomisation (no hyper or hypocaloric diet, no high-protein diet, no prolonged fasting for more than one week, no planned change in the level of sports activity in the next 3 months), * With a personal history of anorexia nervosa, bulimia, or significant eating disorders according to the Investigator, * Taking part in another clinical trial or being in the exclusion period of a previous clinical trial, * Having received, during the last 12 months, indemnities for clinical trial higher or equal to 6000 Euros, * Under legal protection (guardianship, wardship) or deprived of rights following an administrative or judicial decision, * Presenting a psychological or linguistic incapability to sign the ICF, Impossible to contact in case of emergency.
Where this trial is running
Saint-Herblain
- Biofortis — Saint-Herblain, France (Recruiting)
Study contacts
- Study coordinator: Eleonora Rossi, PhD
- Email: eleonora.rossi@biofortis.fr
- Phone: +33 240205799
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.